β2 adrenoceptor ( EC50 = 1 nM )

Olodaterol (0.001~10 nM; fibroblasts) inhibits the motility and proliferation induced by growth factors [2]. Fibroblasts treated with olotadrol (0.1–10 nM) prevent the signaling cascade from being phosphorylated when FGF is present [2]. Concentration-dependently, olapadaterol (0.001~1000 nM; 30 minutes; fibroblasts) raises intracellular cAMP. With a maximum efficacy of 70% at 10 nM, oledacaterol (0 to 10 nM; 30 min; fibroblasts) increased PICP in a concentration-dependent manner. Olodaterol is selective for the β2-AR receptor and has a subnanomolar affinity for it (pKi=9.14) when compared to the β1-AR and β3-AR subtypes [2].

Olodaterol (1 mg/kg; inhalation; day 21) attenuates TGF-β-induced pulmonary fibrosis and speeds up the weight return to control levels (day 21)[2]. After 0.5 hours, olodaterol (0.1 to 3 μg/kg; inhaled; 5h ) and olodaterol (0.3 and 0.6 μg/kg; inhaled; 24 hours)) induce about 60% anesthetic protection[3].

Cell Line: Fibroblasts
Concentration: 0.1~10 nM
Result: Interfered with FGF-induced phosphorylation of signalling cascades.

Lung fibrosis C57BL/6 mice
1 mg/mL
Inhal.; 21 days

Absorption, Distribution and Excretion
Following inhalation of olodartrol, peak plasma concentrations are typically reached within 10 to 20 minutes. In healthy volunteers, the absolute bioavailability of inhaled olodartrol is estimated at approximately 30%, compared to less than 1% after oral administration of a solution. Therefore, the systemic bioavailability of inhaled olodartrol depends primarily on pulmonary absorption, with any swallowed dose contributing negligibly to systemic exposure. Following intravenous administration of [14C]-labeled olodartrol, 38% of the radioactive dose was recovered in the urine and 53% in the feces. After intravenous administration, 19% of the unmetabolized olodartrol was recovered in the urine. Following oral administration, only 9% of olodartrol and/or its metabolites were recovered in the urine, while the majority (84%) were recovered in the feces. The high volume of distribution (1110 L) suggests extensive distribution in tissues.
The total clearance of olodaterol in healthy volunteers was 872 mL/min, and the renal clearance was 173 mL/min.
Metabolism/Metabolites

Olodaterol is primarily metabolized via direct glucuronidation and O-demethylation of the methoxy group. Of the six identified metabolites, only the unbound demethylated product binds to the β2 receptor. However, this metabolite is undetectable in plasma after prolonged inhalation of the recommended therapeutic dose. Cytochrome P450 isoenzymes CYP2C9 and CYP2C8 are involved in the O-demethylation of olodaterol, while the role of CYP3A4 is negligible; while uridine diphosphate glycosyltransferase isoenzymes UGT2B7, UGT1A1, 1A7, and 1A9 are involved in the formation of olodaterol glucuronide.
Biological Half-Life

The terminal half-life after intravenous injection is 22 hours. In contrast, the terminal half-life after inhalation is approximately 45 hours, indicating that the latter is primarily determined by absorption rather than elimination.

Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation
While there is currently no published data on the use of olodaterol during lactation, data on the related drug terbutaline suggest that very small amounts are expected to be excreted into breast milk. Authors of multiple reviews agree that the use of such drugs during lactation is acceptable due to the low bioavailability of inhaled bronchodilators and the low maternal serum concentrations after administration. ◉ Effects on Breastfed Infants
No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk
No published information found as of the revision date.

---

Protein Binding The in vitro binding of olodaterol to human plasma proteins is concentration-independent, with a binding rate of approximately 60%.

[1]. Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β2-adrenoceptor agonists. Bioorg Med Chem. 2020;28(1):115178.

[2]. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis. Br J Pharmacol. 2017;174(21):3848-3864.

[3]. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models [published correction appears in J Pharmacol Exp Ther. 2013 Jul;346(1):161]. J Pharmacol Exp Ther. 2010;334(1):53-62.

Olodaterol belongs to the benzoxazine class of compounds, with the chemical name 6-hydroxy-1,4-benzoxazine-3-one, where the hydrogen at position 4 is replaced by (1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropyl-2-yl]amino}ethyl. It (in hydrochloride form) is used for the long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (including chronic bronchitis and/or emphysema). It is a β-adrenergic agonist and bronchodilator. It belongs to the benzoxazine class of compounds and is also a phenol, aromatic ether, secondary alcohol, and secondary amino compound. It is the conjugate base of olodaterol (1+). Olodaterol is a novel, long-acting β2-adrenergic agonist (LABA) that exerts its pharmacological effects by binding to and activating β2-adrenergic receptors primarily located in the lungs. β2-adrenergic receptors are membrane-bound receptors, normally activated by endogenous adrenaline. Adrenaline transmits signals via downstream L-type calcium channel interactions, mediating smooth muscle relaxation and bronchodilation. Receptor activation stimulates associated G proteins, which in turn activate adenylate cyclase, catalyzing the production of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevations in these two molecules induce bronchodilation by relaxing airway smooth muscle. Olodaterol is used to treat chronic obstructive pulmonary disease (COPD) and its characteristic progressive airflow obstruction through this mechanism. Bronchodilator therapy helps relieve related symptoms such as dyspnea, cough, and sputum production. Studies have shown that a single dose of olodaterol can improve forced expiratory volume in one second (FEV1) in COPD patients within 24 hours, thus allowing for once-daily dosing. Compared to short-acting bronchodilators and twice-daily LABAs, once-daily LABA treatment offers several advantages, including greater convenience and adherence, and improved airflow within 24 hours. Despite similar symptoms, olodartrol is not indicated for the treatment of acute exacerbations of COPD or asthma. Orodartrol is a β2-adrenergic agonist. The mechanism of action of olodartrol is as a β2-adrenergic agonist. See also: Orodartrol hydrochloride (active ingredient).

---

Drug Indications
Olodartrol is indicated for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or asthma.
FDA LabelMechanism of Action
Olodartrol is a long-acting β2-adrenergic agonist (LABA) that exerts its pharmacological action by binding to and activating β2-adrenergic receptors, primarily located in the lungs. β2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous adrenaline. Adrenaline transmits signals through downstream L-type calcium channel interactions, mediating smooth muscle relaxation and bronchodilation. Upon receptor activation, it stimulates the associated G protein, which in turn activates adenylate cyclase, catalyzing the production of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevated levels of these two molecules induce bronchodilation by relaxing airway smooth muscle.

C21H26N2O5

386.44

386.184

868049-49-4

Olodaterol hydrochloride; 869477-96-3

11504295

Light yellow to khaki solid powder

1.3±0.1 g/cm3

649.0±55.0 °C at 760 mmHg

346.3±31.5 °C

0.0±2.0 mmHg at 25°C

1.596

1.17

4

6

7

28

521

1

[C@H](C1C=C(O)C=C2NC(COC=12)=O)(O)CNC(C)(C)CC1C=CC(OC)=CC=1

COUYJEVMBVSIHV-SFHVURJKSA-N

InChI=1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1

6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one

BI1744; BI-1744; BI 1744; Striverdi; Olodaterol

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO: ~77 mg/mL (~199.3 mM)
Ethanol: ~40 mg/mL

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)